Eli Lilly has announced a collaboration with Banner Alzheimer's Institute, which specializes in early identification and tracking of the disease, over a phase III trial of its drug donanemab.
Bloomberg News reports that the US pharmaceutical group was awarded breakthrough therapy status for the drug by the US Food and Drug Authority, FDA.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.